Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$145.61 USD

145.61
1,434,722

+1.83 (1.27%)

Updated Jul 19, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for SRPT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Sarepta Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 1,676 1,989 2,116 1,939 1,125
Receivables 400 215 153 101 91
Notes Receivable 0 0 0 0 0
Inventories 323 204 186 232 171
Other Current Assets 180 150 149 213 82
Total Current Assets 2,579 2,558 2,604 2,485 1,469
Net Property & Equipment 227 180 191 190 130
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 191 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 8 14 14 13
Deposits & Other Assets 137 318 293 204 174
Total Assets 3,265 3,128 3,148 2,985 1,823
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 165 96 77 111 68
Current Portion Long-Term Debt 105 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 315 419 272 194 186
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 50 105 104 111 11
Total Current Liabilities 654 620 453 416 265
Mortgages 0 0 0 0 0
Deferred Taxes/Income 437 485 574 663 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,133 1,544 1,097 992 682
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 41 37 55 71 10
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,405 2,743 2,220 2,223 1,005
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 5,305 4,297 4,135 3,610 3,112
Retained Earnings -4,446 -3,910 -3,207 -2,848 -2,294
Other Equity 1 -2 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 859 385 928 762 818
Total Liabilities & Shareholder's Equity 3,265 3,128 3,148 2,985 1,823
Total Common Equity 859 385 928 762 818
Shares Outstanding 93.50 87.70 87.00 78.90 74.50
Book Value Per Share 9.19 4.39 10.67 9.65 10.98

Fiscal Year End for Sarepta Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 1,391 1,676 1,734 1,861
Receivables NA 379 400 319 237
Notes Receivable NA 0 0 0 0
Inventories NA 374 323 244 227
Other Current Assets NA 322 180 154 148
Total Current Assets NA 2,465 2,579 2,451 2,473
Net Property & Equipment NA 249 227 212 189
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 208 191 176 167
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 176 137 137 163
Total Assets NA 3,224 3,265 3,110 3,126
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 92 165 88 110
Current Portion Long-Term Debt NA 106 105 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 283 315 322 327
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 128 50 40 62
Total Current Liabilities NA 609 654 451 499
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 325 437 485 485
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1,134 1,133 1,237 1,236
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 41 38 36
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 2,263 2,405 2,345 2,384
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 5,372 5,305 5,257 5,193
Retained Earnings NA -4,410 -4,446 -4,492 -4,451
Other Equity NA -1 1 -1 -1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 961 859 764 741
Total Liabilities & Shareholder's Equity NA 3,224 3,265 3,110 3,126
Total Common Equity 0 961 859 764 741
Shares Outstanding 94.50 94.50 93.50 93.50 93.20
Book Value Per Share 0.00 10.17 9.19 8.17 7.96